Should You Invest in the SPDR S&P Biotech ETF (XBI)?

The SPDR S&P Biotech ETF (XBI), a passively managed fund tracking the S&P Biotechnology Select Industry Index, offers broad exposure to the Healthcare - Biotech sector with over $6.22 billion in assets and a low 0.35% expense ratio. While it has delivered strong year-to-date returns of 16.62% (as of 10/13/2025), its 27.77% three-year standard deviation indicates a high-risk profile. With 128 holdings, including Alnylam Pharmaceuticals as its largest, XBI holds a Zacks ETF Rank of 3 (Hold), positioning it as a suitable, albeit volatile, option for targeted sector investment.

Analysis

The SPDR S&P Biotech ETF (XBI) offers a passively managed, cost-effective entry into the Healthcare - Biotech sector, tracking the S&P Biotechnology Select Industry Index. With over $6.22 billion in assets under management and an annual operating expense ratio of 0.35%, it stands out as one of the least expensive options in its category. The fund's modified equal-weight strategy provides diversification across 128 holdings, with the top 10 positions accounting for 28.22% of its total assets. Alnylam Pharmaceuticals Inc (ALNY) is its largest individual holding at 3.47%.

As of October 13, 2025, XBI has demonstrated strong short-term performance, returning 16.62% year-to-date and 9.16% over the last year. However, its risk profile is notably high, evidenced by a 3-year trailing standard deviation of 27.77% and a beta of 0.93, indicating significant volatility relative to the broader market. The ETF's 100% allocation to the Healthcare - Biotech sector concentrates this risk.

The fund carries a Zacks ETF Rank of 3 (Hold), suggesting it is a sufficient option for sector exposure but not a strong buy, based on factors including expected asset class return, expense ratio, and momentum. While XBI's expense ratio is competitive, investors should also consider alternatives like the iShares Biotechnology ETF (IBB), which has a similar AUM of $6.21 billion but a slightly higher expense ratio of 0.44%.

Key Decisions for Investors

• Consider XBI for targeted, cost-effective exposure to the high-growth biotech sector, leveraging its low 0.35% expense ratio and broad diversification across 128 holdings.
• Be prepared for significant volatility, as indicated by XBI's 27.77% three-year trailing standard deviation, and ensure this aligns with your risk tolerance.
• Monitor the fund's performance and the broader biotech sector outlook, especially given its 100% sector allocation and the Zacks ETF Rank of 3 (Hold), and compare it against peers like IBB for relative value.